AstraZeneca reported that its Covid-19 vaccine was 79% effective at preventing severe infection and 100% effective at preventing hospitalization. The company expects to file a submission seeking FDA emergency use authorization in coming weeks.
The Series B round of funding for University of Oxford spinout Vaccitech includes the type of financial backers that could support an IPO. While Vaccitech might be best known for its association with AstraZeneca's Covid-19 vaccine, the startup also has programs for other infectious diseases and cancer.
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
The New York Times had reported that the participant in question was taking part in a Phase II/III trial in the U.K. The event was reported the same day that AstraZeneca's CEO and nine others signed a pledge not to rush development of vaccines against the SARS-CoV-2 virus.
Data from a large Phase II/III study in the U.K. showed that patients requiring respiratory support who received the drug dexamethasone died at lower rates than those who received standard treatments alone.
The drugmaker is partnering with Oxford to develop the adenovirus vector-based vaccine, ChAdOx1 nCoV-19, which entered a Phase I/II clinical trial of more than 1,100 healthy volunteers in the U.K. late last month. Data could be available next month, the company said.